News
Friedreich's ataxia: the pathological iron-redox axis revisited
Dr. Benoit D'Autréaux, Paris-Saclay University, France, will join Redox Medicine 2023 this June to present his recent research on "Friedreich's ataxia: the pathological iron-redox axis revisited".
Friedreich’s ataxia (FA) is the most prevalent autosomic recessive ataxia and is associated with a severe cardiac hypertrophy and diabetes. It is caused by GAA triplet expansion in the 1st intron of the gene encoding the frataxin protein (FXN), a small mitochondrial protein with a central role in iron metabolism.
The primary consequence of the GAA triplet expansions is a defective expression of FXN, with basal protein levels decreased by 65 % to 98 %, which foremost affects the cerebellum, the heart, and the liver. FXN is a central actor of iron metabolism but its exact function has remained highly debated since its discovery. At the cellular level, FA is characterized by a general deficit in the biosynthesis of iron-sulfur (Fe-S) clusters and heme, iron accumulation in mitochondria and sensitivity to oxidative stress.
Based on these phenotypes and the ability of FXN to bind iron, a role as an iron storage or an iron chaperone was initially proposed. This model was later on challenged by several other studies and it is now widely accepted that FXN functions primarily in Fe-S cluster biosynthesis, with iron accumulation, heme deficiency and oxidative stress sensitivity appearing as secondary phenotypes. A picture is now emerging pointing to a unique function of FXN as an enhancer accelerating a key step of sulfur transfer between two components of the Fe-S cluster biosynthetic complex.
Dr. D'Autréaux will present the most recent data on the biochemical function of frataxin and the consequence for therapeutic strategies aiming to cure FA.
Join Redox Medicine 2023 to learn more about Dr. D'Autréaux's interesting talk.
You can submit a related abstract here.
Redox Medicine 2023 Congress
June 21-23, 2023 - Paris, France
Website | LinkedIn | Facebook
The Determination of Intracellular Labile Ironome for Diagnosis and Prognosis of Iron-Related Disorders: the Example of Friedreich’s Ataxia’
Dr. Charareh Pourzand, University of Bath, United Kingdom, will join Redox Medicine 2023 this June to present his recent research on "The Determination of Intracellular Labile Ironome for Diagnosis and Prognosis of Iron-Related Disorders: the Example of Friedreich’s Ataxia’".
Recent studies on human disorders as well as cellular studies with environmental oxidizing agents have indicated that excess accumulation of redox active labile iron (LI) plays a key role in conferring cellular sensitivity to oxidative damage and the resulting pathologies and cell death. The sensitive evaluation of LI distribution in subcellular compartments under physiological and oxidative/ pathological conditions can be beneficial for diagnosis and prognosis of iron-related disorders and the development of highly specific iron chelators as preventive and therapeutic agents for iron-related oxidative injuries and diseases.
Dr. Pourzand and her team have recently developed highly specific iron sensors capable of sensitively monitoring and evaluating the cytosolic, lysosomal and mitochondrial LI levels which together provides the labile ironome profile of cells in oxidative and pathological conditions with potential application as diagnostic or prognostic markers in iron-related disorders.
Using the example of Friedreich’s ataxia, Dr. Pourzand will discuss how labile ironome of individual patients’ cells can be used as a prognostic marker for the promotion and the progression of this neuro-muscular disorder.
Join Redox Medicine 2023 to learn more about Dr. Pourzand's interesting talk.
All innovations regarding redox medicine will be covered during the meeting. You can submit a related abstract here.
Redox Medicine 2023 Congress
June 21-23, 2023 - Paris, France
Website | LinkedIn | Facebook
Redox Medicine & Signaling: Molecular Mechanisms Underlying Age-Related Muscle Decline
Dr. Robert A Heaton from the University of Liverpool, United Kingdom, will join the Redox Medicine 2023 congress and give a presentation entitled "Redox Medicine & Signaling: Molecular Mechanisms Underlying Age-Related Muscle Decline".
Dr. Robert A. Heaton is an early career researcher who has been focusing on REDOX biology and its potential for therapeutic intervention for disease. His previous work has been the first to demonstrate the mitochondrial-lysosomal axis involving the antioxidant CoQ10 in neuronal disease. Currently, his primary research focus is on the effect of aging on the loss of skeletal muscle adaptability to exercise.
Dr. Heaton's current research project, titled "Close regulation of Peroxiredoxin (Prx) oxidation is essential for the maintenance of muscle mass and function in the elderly," centers around investigating the role of Prx peroxide enzymes in the maintenance and function of H2O2 signaling during muscle contractions. His work aims to uncover how attenuation of these delicate pathways may lead to diminished muscle adaptations in aging, and potentially discover new therapeutic avenues for reducing the impact of age-related muscle loss.
Dr. Heaton's upcoming talk will cover the topic of H2O2 signaling during muscle contractions and its importance in muscle adaptations, as well as the techniques he is utilizing to assess these pathways in their in vivo state. His research has the potential to shed light on the molecular mechanisms underlying age-related muscle decline and could have significant implications for developing strategies to mitigate muscle loss in the elderly.
Join Redox Medicine 2023 to benefit from Dr. Heaton's experience in the redox field and learn more about his interesting talk.
All innovations regarding redox medicine will be covered during the meeting. You can submit a related abstract here.
Redox Medicine 2023 Congress
June 21-23, 2023 - Paris, France
Website | LinkedIn | Facebook
Antioxidants & Redox Signaling Journal is a Contributing Partner in Redox Medicine 2023
Antioxidants & Redox Signaling (ARS) Journal is a contributing partner in the 25th International Conference of the Redox Medicine Society. Editor in Cheif of the journal Prof. Chandan K. Sen, Indiana University, USA will be presenting a talk entitled "Redox Medicine 2023: What’s Next?".
Submit your abstracts to be featured in ARS journal
All the conference proceedings will be published in the journal, that is indexed in Medline and of impact factor 7.468. So make sure to submit your abstracts. Abstract submission details.
Recommend subscription to ARS journal
You can recommend a subscription to ARS, to your library and instituion by following this link: https://home.liebertpub.com/publications/antioxidants-and-redox-signaling/4/recommend.
Subscription advantages include:
- ARS is publishing its 38th volume in 2023 and online subscription access can provide a rich archive of searchable content.
- The journal has a stellar Impact Factor of 7.468 and impressive Scopus CiteScore of 16/1.
- Institutional subscription access enhances collaboration among colleagues.
- The ARS editorial board include renowned scholars and researchers, including a Nobel Prize laureate.
- Only 25 days from time of submission to first decision, a benefit of choosing ARS for article publication.
- Opportunity to publish open access.
Redox Medicine 2023 Congress
June 21-23, 2023 - Paris, France
Website | LinkedIn | Facebook
Precision Redox: The Key for Antioxidant Pharmacology
Prof. Chang Chen, Institute of Biophysics, Chinese Academy of Sciences, China, will join Redox Medicine 2023 this June to present about Precision Redox: The Key for Antioxidant Pharmacology.
Prof. Chen will discuss the “5R” principle of precision redox in antioxidant pharmacology: “Right species, Right place, Right time, Right level, and Right target.”
For Prof. Chen, the redox status must be considered in the context of species, time, place, level, and target. The function of a biomacromolecule and its cellular signaling role are closely dependent on redox status. Accurate evaluation of redox status and specific interventions are critical for the success of redox treatments. Precision redox is the key for antioxidant pharmacology. The precise application of antioxidants as nutritional supplements is also key to the general health of the population.
More information about her latest studies.
Join Redox Medicine 2023 to learn more about Prof. Chen's interesting talk. You can submit a related abstract here.
Redox Medicine 2023 Congress
June 21-23, 2023 - Paris, France
Website | LinkedIn | Facebook
More Articles...
- Mitochondrial Involvement in Different Model Systems of Ferroptosis
- Chronobiology : The Reactive Species Interactome-Mitochondria axis, the hands of the circadian clock ?
- Awakening Adult Retinal Stem Cells: A New Function of NOX Signaling in the Xenopus Retina
- Effects of reactive sulfur species in macrophage activation and regulation of apoptosis/necrosis pathways in cancer cells
